Medium-chain triglyceride

Sources of MCTs

MCTs are found in palm kernel oil and coconut oil and can be separated by fractionation. They can also be produced by interesterification. Retail MCT powder is MCT oil embedded in starch and thus contains carbohydrates in addition to fats. It is manufactured by spray drying.

List of MCFAs==

With regard to MCFAs, apart from the above listed straight chain (unbranched chain) fatty acids, side chain (branched chain) fatty acids also exist.

Applications

Calorie restriction

A 2020 systematic review and meta-analysis by Critical Reviews in Food Science and Nutrition supported evidence that MCT decreases subsequent energy intake compared to long-chain triglycerides (LCTs). Despite this, it does not appear to affect appetite, and thus the authors stated that further research is required to elucidate the mechanism by which this occurs.

Dietary relevance

Molecular weight analysis of milk from different species showed that while milk fats from all studied species were primarily composed of long-chain fatty acids (16 and 18 carbons long), approximately 10–20% of the fatty acids in milk from horses, cows, sheep, and goats were medium-chain fatty acids.

Some studies have shown that MCTs can help in the process of excess calorie burning, thus weight loss. MCTs are also seen as promoting fat oxidation and reduced food intake. MCTs have been recommended by some endurance athletes and the bodybuilding community. While health benefits from MCTs seem to occur, a link to improved exercise performance is inconclusive.

Pharmaceutical relevance

MCTs can be used in solutions, liquid suspensions and lipid-based drug delivery systems for emulsions, self-emulsifying drug delivery systems, creams, ointments, gels and foams as well as suppositories. MCTs are also suitable for use as solvent and liquid oily lubricant in soft gels. Brand names of pharma-grade MCT include Kollisolv MCT 70.

Medical relevance

MCTs passively diffuse from the GI tract to the hepatic portal system (longer fatty acids are absorbed into the lymphatic system) without requirement for modification like long-chain fatty acids or very-long-chain fatty acids. In addition, MCTs do not require bile salts for absorption. Patients who have malnutrition, malabsorption or particular fatty-acid metabolism disorders are treated with MCTs because MCTs do not require energy for absorption, use, or storage.

Medium-chain triglycerides are generally considered a good biologically inert source of energy that the human body finds reasonably easy to metabolize. They have potentially beneficial attributes in protein metabolism, but may be contraindicated in some situations due to a reported tendency to induce ketogenesis and metabolic acidosis. However, there is other evidence demonstrating no risk of ketoacidosis or ketonemia with MCTs at levels associated with normal consumption, and that the moderately elevated blood ketones can be an effective treatment for epilepsy.

Due to their ability to be absorbed rapidly by the body, medium-chain triglycerides have found use in the treatment of a variety of malabsorption ailments. MCT supplementation with a low-fat diet has been described as the cornerstone of treatment for Waldmann disease. MCTs are an ingredient in some specialised parenteral nutritional emulsions in some countries. Studies have also shown promising results for epilepsy through the use of ketogenic dieting.

Orally ingested medium chain triglycerides would be very rapidly degraded by first-pass metabolism by being taken up in the liver via the portal vein, and are quickly metabolized via coenzyme A intermediates through β-oxidation and the citric acid cycle to produce carbon dioxide, acetate and ketone bodies.

Technical uses

MCTs are bland compared to other fats and do not generate off-notes (dissonant tastes) as quickly as LCTs. They are also more polar than LCTs. Because of these attributes, they are widely used as carrier oils or solvents for flavours and oral medicines and vitamins.

References

References

1. (2005). "Bailey's Industrial Oil and Fat Products".
2. (2003). "Riegel's Handbook of Industrial Chemistry". Springer.
3. (July 2016). "The Increasing Use of Interesterified Lipids in the Food Supply and Their Effects on Health Parameters". Advances in Nutrition.
4. (June 2013). "Seizure control by ketogenic diet-associated medium chain fatty acids". Neuropharmacology.
5. (2021). "A systematic review and meta-analysis of medium-chain triglycerides effects on acute satiety and food intake". Critical Reviews in Food Science and Nutrition.
6. (September 1967). "Molecular weight distributions of milk fat triglycerides from seven species". Journal of Lipid Research.
7. (December 2003). "Greater rise in fat oxidation with medium-chain triglyceride consumption relative to long-chain triglyceride is associated with lower initial body weight and greater loss of subcutaneous adipose tissue". International Journal of Obesity and Related Metabolic Disorders.
8. (2006). "Medium-chain triglycerides". International Dairy Journal.
9. (March 2002). "Physiological effects of medium-chain triglycerides: potential agents in the prevention of obesity". The Journal of Nutrition.
10. (November 2010). "Medium-chain triglycerides are advantageous in promoting weight loss although not beneficial to exercise performance". International Journal of Food Sciences and Nutrition.
11. (2006). "The Health Professional's Guide to Dietary Supplements". Lippincott Williams & Wilkins.
12. (2012). "Influence of the dietary intake of medium chain triglycerides on body composition, energy expenditure and satiety: a systematic review". Nutricion Hospitalaria.
13. (November 2023). "Analysis of the Physical Characteristics of an Anhydrous Vehicle for Compounded Pediatric Oral Liquids". Pharmaceutics.
14. "Kollisolv MCT 70".
15. (October 2004). "Cellular and physiological effects of medium-chain triglycerides". Mini Reviews in Medicinal Chemistry.
16. (February 2008). "Primary intestinal lymphangiectasia (Waldmann's disease)". Orphanet Journal of Rare Diseases.
17. (July–August 2006). "New parenteral lipid emulsions for clinical use". Journal of Parenteral and Enteral Nutrition.
18. (May 2006). "Parenteral lipid emulsions in paediatrics". Current Opinion in Clinical Nutrition and Metabolic Care.
19. (April 2010). "Efficacy of dietary treatments for epilepsy". Journal of Human Nutrition and Dietetics.
20. (November 2008). "Medium-chain triglyceride (MCT) ketogenic therapy". Epilepsia.
21. (August 2015). "Anticonvulsant properties of an oral ketone ester in a pentylenetetrazole-model of seizure". Brain Research.
22. (April 2002). "Acetoacetate, acetone, and dibenzylamine (a contaminant in l-(+)-beta-hydroxybutyrate) exhibit direct anticonvulsant actions in vivo". Epilepsia.
23. (April 2007). "Ketogenic diet metabolites reduce firing in central neurons by opening K(ATP) channels". The Journal of Neuroscience.
24. (2006). "Handbook of Functional Lipids". Taylor & Francis.